NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $7.25 +0.29 (+4.17%) Closing price 04:00 PM EasternExtended Trading$7.20 -0.04 (-0.62%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ocular Therapeutix Stock (NASDAQ:OCUL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ocular Therapeutix alerts:Sign Up Key Stats Today's Range$6.79▼$7.2750-Day Range$6.96▼$11.7352-Week Range$6.23▼$16.44Volume5.62 million shsAverage Volume4.01 million shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$24.33Consensus RatingModerate Buy Company Overview Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology. Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional. DEXTENZA is approved in the United States for the treatment of ocular itching associated with allergic conjunctivitis and for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is also advancing a pipeline of investigational treatments for retinal diseases and other ophthalmic conditions, including therapies designed for longer-duration drug delivery. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix primarily serves the U.S. ophthalmology market. The company is led by co-founder Antony P. Marucci, who serves as president and chief executive officer. Its products and development programs are supported by research, clinical development and commercial activities focused on the United States.AI Generated. May Contain Errors. Read More Ocular Therapeutix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreOCUL MarketRank™: Ocular Therapeutix scored higher than 55% of companies evaluated by MarketBeat, and ranked 434th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOcular Therapeutix has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOcular Therapeutix has a consensus price target of $24.33, representing about 235.6% upside from its current price of $7.25.Amount of Analyst CoverageOcular Therapeutix has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ocular Therapeutix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.47) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -5.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -5.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ocular Therapeutix's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.07% of the float of Ocular Therapeutix has been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 14.19, which indicates bearish sentiment.Change versus previous monthShort interest in Ocular Therapeutix has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentOcular Therapeutix has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Ocular Therapeutix this week, compared to 6 articles on an average week.Search InterestOnly 13 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows4 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $321,827.00 in company stock.Percentage Held by Insiders3.10% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCUL Stock News HeadlinesStocktwits Pharma Pulse: Roche faces FDA decision, gene-therapy stocks step into focus — the week’s biotech watchlistOctober 4 at 12:04 AM | msn.comOcular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan CapitalOctober 4 at 1:36 AM | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws ScrutinyOctober 2 at 12:52 PM | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) and Cumberland Pharmaceuticals (NASDAQ:CPIX) Critical SurveyOctober 2 at 2:46 AM | americanbankingnews.comOCUL stock on track for worst week in 2.5 years as rivals raise the bar in wet AMDOctober 2 at 1:18 AM | msn.comOcular Therapeutix™ to Participate in October Scientific and Investor ConferencesOctober 1, 2026 | globenewswire.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Needham & Company LLCOctober 1, 2026 | americanbankingnews.comSee More Headlines OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $12.14 at the start of the year. Since then, OCUL stock has decreased by 40.3% and is now trading at $7.25. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings results on Monday, August, 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. The business's revenue for the quarter was down .1% compared to the same quarter last year. When did Ocular Therapeutix IPO? Ocular Therapeutix (OCUL) raised $75 million in an IPO on Friday, July 25th 2014. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/03/2026Today10/05/2026Chardan's 10th Annual Healthcare Conference10/20/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, OCUL's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OCUL CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees325Year Founded2006Price Target and Rating Average Price Target for Ocular Therapeutix$24.33 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+235.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$265.94 million Net Margins-579.10% Pretax Margin-579.10% Return on Equity-59.89% Return on Assets-45.99% Debt Debt-to-Equity Ratio0.14 Current Ratio13.10 Quick Ratio13.03 Sales & Book Value Annual Sales$51.95 million Price / Sales30.65 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book2.36Miscellaneous Outstanding Shares219,620,000Free Float212,808,000Market Cap$1.59 billion OptionableOptionable Beta1.00 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:OCUL) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
